Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
03 February 2023 - 10:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 2, 2023
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
| Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this
Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 2 February 2023 — This company announcement discloses
the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons
in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have
given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo
Nordisk.
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Elisabeth
Dahl Christensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Liselotte
Sofie Hyveled |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo
Nordisk B DK0060534915 |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
1,345
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
1,345 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Liselotte
Sofie Hyveled |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Mette
Bøjer Jensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| |
|
|
| c) |
Price(s) and
volume(s) |
|
Price(s) |
Volume(s) |
|
| |
DKK 0.00 |
75 shares |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
|
|
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Maha
Kutay |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Closely
related to Kasim Kutay, member of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Purchase
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
964.25 |
434
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume |
434 Shares |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
· Price |
DKK
964.25 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
NASDAQ
COPENHAGEN A/S (XCSE) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Thomas
Rantzau |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
86,083
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
86,083 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial
instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
944.76 |
3,396
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
3,396 Shares
DKK 944.76 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
AQUIS
EXCHANGE EUROPE (AQEU) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
942.91 |
13,847
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
13,847 Shares
DKK 942.91 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
CBOE
EUROPE (BEUP) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument, type of instrument, |
Shares |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
Identification
code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
939.70 |
77
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
77 Shares
DKK 939.70 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
CBOE
EUROPE - DXE DARK ORDER BOOK (NL) (CEUD) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
DKK
944.88 |
6,449
shares |
|
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
6,449 Shares
DKK 944.88 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
CBOE
EUROPE - DXE ORDER BOOKS (NL) (CEUX) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
944.03 |
3,503
shares |
| |
| |
| d) |
Aggregated information |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
· Aggregated volume
· Price |
3,503 Shares
DKK 944.03 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
SIGMA
X EUROPE AUCTION BOOK (SGMV) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
942.74 |
38 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
38 Shares
DKK 942.74 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
TURQUOISE
EUROPE (TQEX) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
943.23 |
22,690
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
22,690 Shares
DKK 943.23 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
NASDAQ
COPENHAGEN A/S (XCSE) |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Monique
Carter |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
8,963
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
8,963 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Monique
Carter |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Maziar
Mike Doustdar |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 4 |
Details
of the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
26,984
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
26,984 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Maziar
Mike Doustdar |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument, type of instrument, |
Shares |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
Identification
code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Maziar
Mike Doustdar |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and volume(s) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
Price(s) |
Volume(s) |
|
| DKK
949.99 |
1,434
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
1,434 Shares
DKK 949.99 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
OUTSIDE
A TRADING VENUE |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Ludovic
Helfgott |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
24,286
shares |
| |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
| d) |
Aggregated information
· Aggregated volume
· Price |
24,286 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Ludovic
Helfgott |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume |
75 Shares |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
·
Price |
DKK
0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Ludovic
Helfgott |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
949.99 |
6,929
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
6,929 Shares
DKK 949.99 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
OUTSIDE
A TRADING VENUE |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Karsten
Munk Knudsen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
24,286
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
24,286 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Name
of the Board member/Executive/Associated Person |
Karsten
Munk Knudsen |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Douglas
Langa |
| 2 |
Reason for
the notification |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
26,984
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
26,984 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Douglas
Langa |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Douglas
Langa |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
949.99 |
13,914
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
13,914 Shares
DKK 949.99 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
OUTSIDE
A TRADING VENUE |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Martin
Holst Lange |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Other
transaction (transfer of shares in |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
accordance
with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
10,978
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
10,978 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Martin
Holst Lange |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
| Identification code |
Novo
Nordisk B DK0060534915 |
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and volume(s) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Marcus
Schindler |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
10,978
shares |
| |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
|
|
| d) |
Aggregated information
· Aggregated volume
· Price |
10,978 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Marcus
Schindler |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume |
75 Shares |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| |
· Price |
DKK
0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Marcus
Schindler |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Sale
of shares |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
944.96 |
5,000
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
5,000 Shares
DKK 944.96 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
NASDAQ
COPENHAGEN A/S (XCSE) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board member/Executive/Associated
Person |
Camilla
Sylvest |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
24,286
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
24,286 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Name
of the Board member/Executive/Associated Person |
Camilla
Sylvest |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Henrik
Ehlers Wulff |
| 2 |
Reason for
the notification |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with Long Term Incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
26,984
shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
26,984 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name of the Board
member/Executive/Associated Person |
Henrik
Ehlers Wulff |
| 2 |
Reason for
the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial notification/Amendment |
Initial
notification |
| 3 |
Details of
the issuer |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details of
the transaction(s) |
| a) |
Description of the financial instrument,
type of instrument, |
Shares |
|
|
| Identification code |
Novo Nordisk B DK0060534915 |
|
| b) |
Nature of the transaction |
Other transaction (transfer of shares in
accordance with restricted stock unit incentive programme) |
| c) |
Price(s) and
volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
75 shares |
| |
| |
| d) |
Aggregated information
· Aggregated volume
· Price |
75 Shares
DKK 0.00 |
| e) |
Date of the transaction |
2023-02-01 |
| f) |
Place of the transaction |
Outside
a trading venue |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered
in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine
disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately
cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
Contact for further information
| Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
| |
|
| Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
| |
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
Company announcement No 6 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 2, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024
